Navigation Links
Cardium Selected for Inclusion in Russell Microcap Index
Date:6/24/2008

-r-co.com" target="_new">http://www.t-r-co.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that inclusion in the Russell Microcap Index will broaden our investor exposure, or otherwise benefit Cardium or its stock, that our products and product candidates will be successfully advanced and will prove to be sufficiently safe and effective, or that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive. Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and therapeutic hypothermia devices and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2008 Cardium Therapeutics, Inc. All rights reserved.

For Terms of Use Privacy P
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
2. Cardium Launches New AWARE Clinical Study Website
3. Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability
4. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
5. Cardium Reports on First Quarter 2008 Highlights and Financial Results
6. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
7. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
8. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
9. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
10. Cardium Completes $5.3 Million Registered Direct Offering
11. Cardium Announces $5.3 Million Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... The report “Pharmacy Automation Systems Market ... Labeling Systems, Table-top Counters) by End-user (Inpatient Pharmacy ... Trends to 2019” analyzes and studies the major ... Europe, Asia-Pacific, and the Rest of the World ... figures spread through 300 pages and in-depth TOC ...
(Date:10/20/2014)... /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... to $5.8 million and provides a good start to Q4.  The ... America and one in the Middle East ... record levels," said Peter Bruijns , President & CEO. "Total ... Q3 than they have been for any complete year since the ...
(Date:10/20/2014)... PLAINSBORO, N.J. (PRWEB) October 20, 2014 ... that the Sidney Kimmel Cancer Center at Thomas ... program. , Through the Strategic Alliance Partnership ... and OncLive will collaborate to raise awareness of ... cancer treatment, and other projects. Clinicians and other ...
(Date:10/19/2014)... OCTOBER 20-22, 2014: The 9th Annual ... take place at the Congress Center Basel, ... now available at http://www.abim.ch . ... from all over the globe will exchange ... products and developments on the world market. ...
Breaking Biology Technology:Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... PRXL ), a leading global biopharmaceutical services,organization, ... Goldberg, M.D.,to Chief Operating Officer (COO). Dr. Goldberg ... Perceptive Informatics at,PAREXEL. He will continue to oversee ... von Rickenbach, Chairman and Chief Executive Officer of ...
... Sagent Pharmaceuticals, Inc.,a privately-held specialty pharmaceutical company, today ... USP, and cefuroxime for,injection, USP, two broad spectrum ... Sagent,s ceftriaxone for,injection will be available to the ... single,dose vials, as well as 1g and 2g ...
... PALO ALTO, Calif., July 16 Jazz,Pharmaceuticals, Inc. ... has entered,into definitive agreements with selected investors to ... of (i) one share of the Company,s,common stock, ... (ii) a,warrant to purchase 0.45 of a share ...
Cached Biology Technology:PAREXEL Promotes Dr. Mark A. Goldberg to Chief Operating Officer 2PAREXEL Promotes Dr. Mark A. Goldberg to Chief Operating Officer 3PAREXEL Promotes Dr. Mark A. Goldberg to Chief Operating Officer 4Sagent Pharmaceuticals Launches Ceftriaxone, USP, and Cefuroxime for Injection, USP 2Sagent Pharmaceuticals Launches Ceftriaxone, USP, and Cefuroxime for Injection, USP 3Jazz Pharmaceuticals Announces $26.0 Million Registered Direct Offering 2Jazz Pharmaceuticals Announces $26.0 Million Registered Direct Offering 3
(Date:10/15/2014)... As our ability to assess the pandemic risk from ... developments, we must not allow ourselves to become complacent ... an international consortium of scientists. , Influenza pandemics arise ... have yet to develop widespread immunity – spreads in ... in the past 100 years, the worst of which ...
(Date:10/15/2014)... increased resistance to bacterial pneumonia in female mice to ... , Females are naturally more resistant to respiratory infections ... shown that increased resistance to bacterial pneumonia in female ... 3 (NOS3). They also show that this enzyme is ... hormone estrogen. , The team, lead by Professor Lester ...
(Date:10/14/2014)... thieves, prostate cancer tumors scavenge and hoard copper that ... avarice may be a fatal weakness. , Researchers ... prostate cancer cells by delivering a trove of copper ... cells brimming with the mineral, leaving non-cancer cells healthy. ... commercially available for other uses, could soon be tested ...
Breaking Biology News(10 mins):Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Prostate cancer's penchant for copper may be a fatal flaw 2
... have devised a means of identifying partial, distorted, scratched, ... seconds. Previous techniques have tried to identify a ... match them against a database of templates. The University ... each print and transform the topological pattern into a ...
... issue of G&D, Dr. Guillermo Oliver (St. ... evidence to resolve a century-old debate over the ... development of the lymphatic vasculature is integral to ... and maintaining tissue fluid levels) and disease (lymphedema ...
... Acid rain was one of the worlds worst pollution problems ... Britain, as well as Europe and North America. In ... been acidified, harming fish, stream insects and river birds such ... has been taken across Europe to clean up acid pollutants ...
Cached Biology News:New technology identifies warped fingerprints at warp speed 2Recovery from acid rain 'much slower than expected' 2
Low melting point. Ideally suited for in gel enzymatic reactions. Gelling temp. 24-28C Melting temp. 65C. EEO 0.12 Resolution 0.5-20 kb; Rnase/Dnase: none detected....
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
...
...
Biology Products: